Výsledky vyhledávání - "Emma Sturgill"

Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics

Autor: Denise A. Yardley, Carissa Jones, Daniel Schlauch, David R. Spigel, Rebecca Lachs, Erika Hamilton, Andrew J. McKenzie, Howard A. Burris, Emma Sturgill, Mythili Shastry, Amanda Misch, Suzanne F. Jones

Publikováno v: JCO Precision Oncology. :1297-1311

PURPOSE Molecular biomarkers informing disease diagnosis, prognosis, and treatment decisions in patients with breast cancer are being uncovered by next-generation sequencing (NGS) technologies. In this study, we survey how NGS is used for patients wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08da20d1fef52a7400b706a06069d12f
https://doi.org/10.1200/po.20.00469

Zobrazit plný text záznamu

Abstract PS18-34: Physician adoption and molecular landscape of next-generation sequencing in breast cancer patients from community-based clinics

Autor: Rebecca Lachs, Carissa Jones, Erika Hamilton, Andrew J. McKenzie, Mythili Shastry, Amanda Misch, Emma Sturgill, Suzanne F. Jones, Denise A. Yardley, David R. Spigel, Daniel Schlauch, Howard A. Burris

Publikováno v: Cancer Research. 81:PS18-34

Background: Molecular biomarkers such as the expression status of hormone receptors (HR) and HER2 influence disease diagnosis, prognosis, and treatment decisions in breast cancer patients. Recent advances in genetic sequencing technologies and target

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::31eb69064eb6a19bbaaed1a5d85ae963
https://doi.org/10.1158/1538-7445.sabcs20-ps18-34

Zobrazit plný text záznamu

Implementation of a virtual, on-demand, molecular tumor board at a large, multi-clinic, community oncology practice

Autor: Andrew Jacob McKenzie, Carissa Jones, Emma Sturgill, Mary Lynne Capps, Larry Edward Bilbrey, David R. Spigel, Meredith McKean, Stephen Matthew Schleicher

Publikováno v: Journal of Clinical Oncology. 40:96-96

96 Background: Despite the availability of molecularly-targeted agents for the treatment of many cancer types, gaps remain in integrating comprehensive precision oncology decision support tools and services into routine clinical practice. Molecular T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9c619d7b4d9e86be61c6e1a2eed6a417
https://doi.org/10.1200/jco.2022.40.28_suppl.096

Zobrazit plný text záznamu

Variable detection of actionable alterations across racial groups and association with testing patterns

Autor: Emma Sturgill, Jessica Correia, Cooper Schumacher, Daniel Luckett, Suzanne Fields Jones, Howard A. Burris III, David R. Spigel, Andrew Jacob McKenzie

Publikováno v: Journal of Clinical Oncology. 40:3116-3116

3116 Background: Molecular landscape studies are critical to biomarker discovery and precision oncology research. However, non-White patients (pts) have historically been under-represented. In this study, we examine clinico-genomic data from a networ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dcee64355b557c48cc596a65a79d05a8
https://doi.org/10.1200/jco.2022.40.16_suppl.3116

Zobrazit plný text záznamu

De novo EGFR T790M mutations in a community-based oncology practice

Autor: Marilyn Elaine Holt, Amanda Misch, Smita K. Rao, Emma Sturgill, Carissa Jones, Daniel Schlauch, Daniel Luckett, David R. Spigel, Suzanne Fields Jones, Andrew Jacob McKenzie

Publikováno v: Journal of Clinical Oncology. 40:3146-3146

3146 Background: With the 2018 FDA approval of osimertinib for first-line treatment in EGFR-mutated lung cancers, the prevalence of acquired EGFR T790M mutations is expected to decrease, heightening the significance of de novo T790M mutations. Previo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9fd84404c0a2be67d7c7558f50c0f134
https://doi.org/10.1200/jco.2022.40.16_suppl.3146

Zobrazit plný text záznamu

Concordance of blood and tissue TMB from NGS testing in real-world settings and their ability to predict response to immunotherapy

Autor: Howard A. Burris, Andrew J. McKenzie, Xiaotong Fu, Suzanne F. Jones, David R. Spigel, Daniel Luckett, Emma Sturgill, Amanda Misch, Carissa Jones

Publikováno v: Journal of Clinical Oncology. 39:2540-2540

2540 Background: Tumor mutational burden (TMB) detected by tissue-based Next Generation Sequencing (NGS) is a biomarker for immunotherapy (IO) response. Plasma-based NGS vendors have developed methods for quantifying TMB from circulating tumor DNA; h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be0262ae3d7d2b0099e402150d668ed3
https://doi.org/10.1200/jco.2021.39.15_suppl.2540

Zobrazit plný text záznamu

Impact of immune checkpoint inhibitor (CPI) and EGFR tyrosine kinase inhibitor (TKI) sequence on time to treatment failure (TTF) among EGFR plus NSCLC treated in a community-based cancer research network

Autor: Caressa Lietman, Melissa Lynne Johnson, Emma Sturgill, Rebecca Lachs, Andrew J. McKenzie, David R. Spigel, Carissa Jones, Amanda Misch, Suzanne F. Jones

Publikováno v: Journal of Clinical Oncology. 39:9099-9099

9099 Background: The development of CPIs and driver-targeted TKIs has transformed the treatment of NSCLC and increased survival rates. However, the role of CPIs in patients with oncogenic-driven NSCLC remains an area of investigation. We sought to ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::32dd18cd8610cd795e5b432e7c3f1f54
https://doi.org/10.1200/jco.2021.39.15_suppl.9099

Zobrazit plný text záznamu

Real-world data evaluating immunotherapy markers and checkpoint inhibitor response among GI cancers in a large community-based oncology network

Autor: Carissa Jones, Rebecca Lachs, Emma Sturgill, Amanda Misch, Caressa Lietman, Suzanne Fields Jones, Howard A. Burris III, Shiraj Sen, Johanna C. Bendell

Publikováno v: Journal of Clinical Oncology. 39:113-113

113 Background: Checkpoint inhibitor (CPI) therapies have shown prolonged survival in patients (pts) with microsatellite instability (MSI). Tumor mutation burden (TMB) has also been associated with benefit from CPIs, with pembrolizumab recently appro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e22111dc47daff922ffba7ffb1f3ddbe
https://doi.org/10.1200/jco.2021.39.3_suppl.113

Zobrazit plný text záznamu

Clinical and genomic analysis of non-small cell lung cancer (NSCLC) patients with MET exon14 skipping (METex14) mutations and responses to anti-MET therapy

Autor: Andrew McKenzie, Arielle Fisher, Mick Correll, Carissa Jones, Jessica Correia, James Thurber, Amanda Misch, Jessica Heritage, Emma Sturgill, Suzanne Fields Jones, Melissa Lynne Johnson, David R. Spigel

Publikováno v: Journal of Clinical Oncology. 38:9613-9613

9613 Background: MET is a validated oncogene for molecular targeted therapy in non-small-cell lung cancer (NSCLC), and METex14 mutations result in MET overexpression. Studies with MET-targeting therapies have demonstrated high objective response rate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8cfd871fde01c510d97062c8b994d8b2
https://doi.org/10.1200/jco.2020.38.15_suppl.9613

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání